vs

Side-by-side financial comparison of Beeline Holdings, Inc. (BLNE) and INVO Fertility, Inc. (IVF). Click either name above to swap in a different company.

Beeline Holdings, Inc. is the larger business by last-quarter revenue ($1.9M vs $1.8M, roughly 1.1× INVO Fertility, Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -445.0%, a 294.5% gap on every dollar of revenue. INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-21.5M). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs -33.0%).

Beeline or билайн is a mobile network operator brand operating in Russia under PJSC VimpelCom, and in Kazakhstan, Kyrgyzstan and Uzbekistan under VEON Ltd. Beeline is Russia's fourth-largest mobile network operator, and main competitors being MTS, MegaFon and T2.

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

BLNE vs IVF — Head-to-Head

Bigger by revenue
BLNE
BLNE
1.1× larger
BLNE
$1.9M
$1.8M
IVF
Higher net margin
IVF
IVF
294.5% more per $
IVF
-150.5%
-445.0%
BLNE
More free cash flow
IVF
IVF
$19.7M more FCF
IVF
$-1.8M
$-21.5M
BLNE
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
-33.0%
BLNE

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BLNE
BLNE
IVF
IVF
Revenue
$1.9M
$1.8M
Net Profit
$-8.4M
$-2.6M
Gross Margin
Operating Margin
-418.4%
-93.1%
Net Margin
-445.0%
-150.5%
Revenue YoY
22.6%
Net Profit YoY
-16.1%
-62.2%
EPS (diluted)
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLNE
BLNE
IVF
IVF
Q4 25
$1.9M
Q3 25
$2.3M
$1.8M
Q2 25
$1.7M
$1.9M
Q1 25
$1.8M
$1.6M
Q4 24
$1.7M
Q3 24
$783.0K
$1.4M
Q2 24
$3.1M
$1.8M
Q1 24
$2.5M
$1.6M
Net Profit
BLNE
BLNE
IVF
IVF
Q4 25
$-8.4M
Q3 25
$-3.9M
$-2.6M
Q2 25
$-4.1M
$-5.3M
Q1 25
$-6.8M
$-17.4M
Q4 24
$-3.6M
Q3 24
$-1.4M
$-1.6M
Q2 24
$-1.5M
$-2.2M
Q1 24
$-1.3M
$-1.6M
Gross Margin
BLNE
BLNE
IVF
IVF
Q4 25
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
25.5%
31.0%
Q2 24
5.0%
53.1%
Q1 24
7.5%
45.3%
Operating Margin
BLNE
BLNE
IVF
IVF
Q4 25
-418.4%
Q3 25
-120.9%
-93.1%
Q2 25
-229.0%
-160.4%
Q1 25
-268.7%
-1042.1%
Q4 24
-202.0%
Q3 24
-55.6%
-90.7%
Q2 24
-11.4%
-100.9%
Q1 24
-18.5%
-95.7%
Net Margin
BLNE
BLNE
IVF
IVF
Q4 25
-445.0%
Q3 25
-167.2%
-150.5%
Q2 25
-237.3%
-283.6%
Q1 25
-372.4%
-1060.1%
Q4 24
-211.3%
Q3 24
-173.6%
-113.8%
Q2 24
-48.6%
-122.2%
Q1 24
-52.0%
-101.3%
EPS (diluted)
BLNE
BLNE
IVF
IVF
Q4 25
Q3 25
$-0.20
$-0.77
Q2 25
$-0.64
$-13.30
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$-6.60
$-15.11
Q2 24
$-8.74
$-22.39
Q1 24
$-0.78
$-7.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLNE
BLNE
IVF
IVF
Cash + ST InvestmentsLiquidity on hand
$3.1M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$53.6M
$5.8M
Total Assets
$70.2M
$18.8M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLNE
BLNE
IVF
IVF
Q4 25
$3.1M
Q3 25
$1.3M
Q2 25
$6.3M
Q1 25
$1.5M
Q4 24
Q3 24
$310.0K
Q2 24
$420.0K
Q1 24
$147.0K
Total Debt
BLNE
BLNE
IVF
IVF
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
$8.2M
Q2 24
$8.1M
Q1 24
$8.1M
Stockholders' Equity
BLNE
BLNE
IVF
IVF
Q4 25
$53.6M
Q3 25
$51.7M
$5.8M
Q2 25
$54.6M
$2.6M
Q1 25
$47.1M
$3.3M
Q4 24
$12.7M
Q3 24
$-2.5M
$-23.3K
Q2 24
$-1.9M
$1.4M
Q1 24
$-476.0K
$10.2K
Total Assets
BLNE
BLNE
IVF
IVF
Q4 25
$70.2M
Q3 25
$63.2M
$18.8M
Q2 25
$68.6M
$19.3M
Q1 25
$63.8M
$31.7M
Q4 24
$46.4M
Q3 24
$16.2M
$17.0M
Q2 24
$16.6M
$17.8M
Q1 24
$17.0M
$17.3M
Debt / Equity
BLNE
BLNE
IVF
IVF
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLNE
BLNE
IVF
IVF
Operating Cash FlowLast quarter
$-21.4M
$-1.8M
Free Cash FlowOCF − Capex
$-21.5M
$-1.8M
FCF MarginFCF / Revenue
-1143.3%
-101.6%
Capex IntensityCapex / Revenue
0.8%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLNE
BLNE
IVF
IVF
Q4 25
$-21.4M
Q3 25
$-5.8M
$-1.8M
Q2 25
$-4.1M
$-1.7M
Q1 25
$-1.5M
$-3.5M
Q4 24
$-617.4K
Q3 24
$-652.0K
$-640.8K
Q2 24
$-872.0K
$-1.5M
Q1 24
$-82.0K
$-260.6K
Free Cash Flow
BLNE
BLNE
IVF
IVF
Q4 25
$-21.5M
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
FCF Margin
BLNE
BLNE
IVF
IVF
Q4 25
-1143.3%
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Capex Intensity
BLNE
BLNE
IVF
IVF
Q4 25
0.8%
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLNE
BLNE

Beeline Title Holdings$1.4M73%
Other$498.0K27%

IVF
IVF

Segment breakdown not available.

Related Comparisons